CSL

CSL Limited is an Australian multinational biotechnology company headquartered in Melbourne, Australia. Founded in 1916, CSL develops and manufactures biotherapies and vaccines that treat serious medical conditions. The company’s business is organized into three core segments: CSL Behring (plasma-derived and recombinant therapies), Seqirus (influenza vaccines), and CSL Vifor (iron deficiency and nephrology therapies). CSL’s products address diseases in immunology, hematology, respiratory, and cardiovascular health. The company operates manufacturing and R&D facilities across Australia, the United States, Europe, and Asia. CSL maintains compliance with global pharmaceutical and biological safety regulations, luding FDA, EMA, and TGA standards. For fiscal year 2024, CSL reported total revenue of approximately US$14.9 billion.